rva Neurosciences Announces Completion Of FDA Review Of Investigational New Drug Application For MIN-202 And Plans For First U.S.-Based Clinical Trial
September 22, 2014 at 08:32 AM EDT
Minerva Neurosciences, Inc. (Nasdaq: NERV), a leader in the development of new therapies to treat neuropsychiatric diseases and ...
